Inflammatory breast cancer

被引：24

作者：

Cariati, M ^{[1
]}

Bennett-Britton, TM ^{[1
]}

Pinder, SE ^{[1
]}

Purushotham, AD ^{[1
]}

机构：

[1] Univ Cambridge Hosp, NHS Fdn Trust, Cambridge Breast Unit, Addenbrookes Hosp, Cambridge CB2 2QQ, England

来源：

SURGICAL ONCOLOGY-OXFORD | 2005年 / 14卷 / 03期

关键词：

inflammatory breast cancer; multiniodality treatment;

D O I：

10.1016/j.suronc.2005.07.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Background: "Inflammatory" breast cancer is a rare and very aggressive form of the disease characterised by rapid onset and dismal outcome. Methods: This review describes the clinical and molecular aspects of inflammatory breast cancer. The relevant English language literature on of inflammatory breast cancer was searched via Medline and ISI Web of Knowledge(SM) Cross Search (1924-2005), cross-referencing with key articles on the subject. Results and conclusion: An increasing body of evidence demonstrates that inflammatory breast cancer is a unique form of breast cancer. A prompt diagnosis and multidisciplinary approach (based on neoadjuvant chemotherapy, loco-regional treatment with surgery and/or radiotherapy, followed in some cases by adjuvant systemic therapy) are the two factors most likely to have an impact on survival. As the molecular basis of the disease is becoming increasingly more defined, new potential therapeutic targets may arise in the future. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：133 / 143

页数：11

共 89 条

[1]

Alpaugh ML, 1999, CANCER RES, V59, P5079

[2]

Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma [J].

Alpaugh, ML ;

Tomlinson, JS ;

Kasraeian, S ;

Barsky, SH .

ONCOGENE, 2002, 21 (22) :3631-3643

[3]

American Joint Committee on Cancer, 1997, AJCC CANC STAG MAN, P171

[4]

Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: Distinct clinicopathologic entities? [J].

Anderson, WF ;

Chu, KC ;

Chang, S .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2254-2259

[5]

BARBER KW, 1961, SURG GYNECOL OBSTET, V112, P406

[6]

BARKER JL, 1980, CANCER, V45, P625, DOI 10.1002/1097-0142(19800215)45:4<625::AID-CNCR2820450402>3.0.CO

[7]

2-V

[8]

Bell C., 1814, SYSTEM OPERATIVE SUR

[9]

Gene expression profiling identifies molecular subtypes of inflammatory breast cancer [J].

Bertucci, F ;

Finetti, P ;

Rougemont, J ;

Charafe-Jauffret, E ;

Cervera, N ;

Tarpin, C ;

Nguyen, C ;

Xerri, L ;

Houlgatte, M ;

Jacquemier, J ;

Viens, P ;

Birnbaum, D .

CANCER RESEARCH, 2005, 65 (06) :2170-2178

[10]

Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy [J].

Bertucci, F ;

Finetti, P ;

Rougemont, J ;

Charafe-Jauffret, E ;

Nasser, V ;

Loriod, W ;

Camerlo, J ;

Tagett, R ;

Tarpin, C ;

Houvenaeghel, G ;

Nguyen, C ;

Maraninchi, D ;

Jacquemier, J ;

Houlgatte, R ;

Birnbaum, D ;

Viens, P .

CANCER RESEARCH, 2004, 64 (23) :8558-8565

← 1 2 3 4 5 6 7 8 9 →